Bionexus enters agreements with Fidelion Diagnostics, Tongshu Biotechnology

BioNexus Gene Lab (BGLC) announced it has entered into definitive agreements with Fidelion Diagnostics and Tongshu Biotechnology, among other parties, to commercialize VitaGuard, a high-fidelity, tumor-naive liquid-biopsy platform for minimal residual disease, MRD. The parties executed a Share Subscription and Shareholders’ Agreement aligning ownership and governance around a rapid Southeast Asia rollout. The collaboration is intended to support the development and planned commercialization of MRD testing in Southeast Asia through aligned ownership, licensing and operational support. Just as the sub-$1,000 genome unlocked mainstream sequencing, BGLC, Fidelion, and Tongshu aim to deliver the same cost-curve collapse for MRD.